Financial Analysts Roundtable: The Safety Climate, Portfolio Management, And More Restructuring In 2005
Executive Summary
Three large-cap pharmaceutical analysts sat down with "The Pink Sheet" in January to discuss the future of the drug industry. Below are excepts from a conversation with Goldman Sachs' Jim Kelly, Morgan Stanley's Jami Rubin and Deutsche Bank's Barbara Ryan